Elevance Health, Inc. (NYSE: ELV) stands as a formidable entity in the healthcare plans sector, boasting a substantial market capitalization of $86.86 billion. This Indianapolis-based company, formerly known as Anthem, Inc., has made a significant impact since its rebranding in June 2022, continuing to deliver a wide array of health benefits and services across the United States. With its strategic focus on diversification in healthcare services, Elevance Health continues to attract attention from investors and analysts alike.
The current share price of Elevance Health is $400.54, reflecting a modest price change of 0.01%. However, it is the potential upside of 12.12%, based on an average target price of $449.10, that draws investor interest. The analyst sentiment is notably bullish, with 15 buy ratings against 7 hold ratings and zero sell ratings. The target price range from $393.00 to $492.00 suggests a strong confidence in the company’s future performance.
In terms of valuation, Elevance Health presents a forward P/E ratio of 13.53, indicating investor expectations of future growth despite the absence of trailing P/E and PEG ratios. The company’s revenue growth stands at 1.40% with an earnings per share (EPS) of 22.59, delivering a respectable return on equity of 11.13%. These figures highlight Elevance Health’s ability to generate solid returns for its shareholders.
The company also offers a dividend yield of 1.72% with a payout ratio of 30.34%, making it an attractive option for income-focused investors. The free cash flow of over $4.3 billion further underscores its financial robustness and capacity to sustain its dividend payouts while funding growth initiatives.
From a technical perspective, Elevance Health’s stock is trading above its 50-day moving average of $394.74 and significantly above its 200-day moving average of $355.16. This trend, coupled with a Relative Strength Index (RSI) of 45.17, suggests a stable momentum without any indication of being overbought or oversold. The MACD and Signal Line readings of 1.94 and 0.57 respectively reinforce a neutral to slightly bullish outlook.
Elevance Health’s comprehensive portfolio includes health plans and services for a diverse clientele, ranging from individuals to large employer groups, and governmental programs like Medicare and Medicaid. Its pharmacy services, under the CarelonRx brand, cover everything from home delivery to specialty pharmacies, while its Carelon Services division enhances healthcare delivery with palliative and virtual care, and comprehensive care management services.
For investors, Elevance Health represents a compelling opportunity in the healthcare sector. Its strategic initiatives and diversified service offerings position it well to capitalize on the growing demand for comprehensive healthcare solutions. With strong analyst ratings and a promising potential upside, Elevance Health is worth considering for those looking to invest in a resilient and adaptable healthcare company.
